NEWS
OKLAHOMA CITY – A newly approved National Cancer Institute-funded clinical trial aims to improve survival for head and neck cancer patients whose disease returns after radiation therapy – a setback that affects up to 40% of patients and is often associated with poor outcomes.
For these patients, surgery is currently the standard treatment, typically targeting tumors in the mouth, throat or lymph nodes of the neck. This Phase II trial will examine whether giving chemotherapy, or chemotherapy combined with immunotherapy, before surgery can improve survival compared with surgery alone.
“Even when a patient is a good surgical candidate, the operation is often aggressive and life-altering. It can mean losing the voice box, removing much of the tongue, or risking serious complications in the neck, and despite all that, outcomes are still not where we want them to be. We hope this trial identifies a treatment that will help patients live longer without the cancer returning,” said Christina Henson, M.D., associate professor at the University of Oklahoma College of Medicine and radiation oncologist at the OU Health Stephenson Cancer Center. Henson is the radiation oncology chair for the trial, which will enroll patients in Oklahoma and across the United States.
Patients deemed surgical candidates will be randomly assigned to receive chemotherapy (carboplatin and paclitaxel) before surgery; the same chemotherapies plus the immunotherapy drug cemiplimab before surgery; or surgery alone. Cemiplimab, which harnesses the body’s own immune system to fight the cancer, is a PDL1 inhibitor. The drug targets cancers that are positive for PDL1, a protein marker indicating the tumor may be vulnerable to immunotherapy. Most head and neck cancers are PDL1-positive, Henson said.
Henson’s colleague Mark Newpower, Ph.D., an assistant professor in the OU College of Medicine, is the medical physics chair for the trial. Patients with especially high-risk cancer may receive radiation therapy following surgery.
“We have worked to standardize the technical details of this trial. It has been gratifying to contribute the institutional knowledge of our radiation oncology department,” said Newpower, who is the lead proton physicist for OU Health Stephenson Cancer Center.
For more information about the trial, visit https://clinicaltrials.gov/study/NCT07195734.
About the University of Oklahoma
Founded in 1890, the University of Oklahoma is a public research university with campuses in Norman, Oklahoma City and Tulsa. As the state’s flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. In Oklahoma City, the OU Health Campus is one of the nation’s few academic health centers with seven health profession colleges located on the same campus. The OU Health Campus serves approximately 4,000 students in more than 70 undergraduate and graduate degree programs spanning Oklahoma City and Tulsa and is the leading research institution in Oklahoma. For more information about the OU Health Campus, visit www.ouhsc.edu.
Stefano Tarantini, an assistant professor in the Department of Neurosurgery at the University of Oklahoma College of Medicine, spends his days in the laboratory searching for answers to the cognitive decline that too often plagues older adults.
Researchers at the University of Oklahoma have developed new hybrid materials that challenge conventional thinking about how light-emitting compounds work and could advance the field of fast radiation detection.
The University of Oklahoma honored the legacy of the late Berrien Moore III, who served as dean of the College of Atmospheric and Geographic Sciences and director of the National Weather Center from 2010 until his passing in December 2024, with a dedication ceremony for the Oklahoma Weather Lab (OWL) broadcast space at the National Weather Center.
